Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.58 |
| ▸ | WNT1 | P04628 | 5/20 | 0.53 |
| ▸ | GSK3B | P49841 | 5/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339942 | 0.85 | KMT2A (0.54) | SLC5A7WNT1GSK3BDYRK1APOLB | |
| SCHEMBL6477259 | 0.85 | OPRK1 (0.54) | SLC5A7WNT1GSK3BDYRK1ARAB9A | |
| SCHEMBL22174106 | 0.84 | JAK3 (0.58) | SLC5A7RAB9APOLBSCN9AMEN1 | |
| SCHEMBL18871751 | 0.84 | OPRK1 (0.69) | OPRK1 | |
| Hydrochloric Acid SCHEMBL4492052 | 0.83 | OPRK1 (0.67) | OPRK1 | |
| SCHEMBL10262389 | 0.80 | RAB9A (0.59) | SLC5A7GSK3BDYRK1ARAB9AOPRK1 | |
| SCHEMBL12188628 | 0.80 | L3MBTL3 (0.58) | CCR3SCN9AMEN1KMT2A | |
| SCHEMBL6487958 | 0.80 | KMT2A (0.51) | SLC5A7RAB9ACCR3OPRK1NPC1 | |
| Hydrochloric Acid SCHEMBL4508721 | 0.79 | NPC1 (0.57) | SLC5A7WNT1GSK3BDYRK1ARAB9A | |
| SCHEMBL4933296 | 0.78 | SLC5A7 (0.60) | SLC5A7RAB9APOLBCCR3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |